CAS: 168273-06-1; Rimonabant

上下游产品

1-Aminopiperidine 5-(4-chlorophenyl)-1-(2,4-dichlorophenyl)-4-methyl-1H-pyrazole-3-carbonyl chloride 4-(4-chlorophenyl)-3-methyl-2,4-dioxo-N-piperidin-1-yl-butyramide 2,4-dichlorophenyl hydrazine hydr°ChlorideN-(piperidin-1-yl)-5-(4-chlorophenyl)-1-(2,4-dichloro-6-iodophenyl)-4-methyl-1H-pyrazole-3-carboxamide 5-(4-chlorophenyl)-1-(2,4-dichlorophenyl)-4-methyl-N-(piperidin-1-yl)pyrazole-3-carboxamide hydrate rimonabant hydr°Chloride 5-(4-chlorophenyl)-1-(2,4-dichlorophenyl)-4-methyl-N-piperidin-1-yl-1H-pyrazole-3-carboxamide isopropyl alcohol solvate

5-(4-氯苯基)-1-(2,4-二氯苯基)-4-甲基-1H-吡唑-3-羧酸乙酯置于氯化亚砜,N,N-二异丙基乙胺,Potassium Hydroxide体系中,用 乙醇,氯仿,甲苯 用作溶剂,化学反应 18.5H,反应生成利莫那班
参考文献:Synthesis,Hypoglycemic Activity And Molecular Modeling Studies Of Pyrazole-3-Carbohydrazides Designed By A Comfa Model
标题:Synthesis,Hypoglycemic Activity And Molecular Modeling Studies Of Pyrazole-3-Carbohydrazides Designed By A Comfa Model
摘要:Diabetes And Obesity Are Two Universal Health Problems That Constitute A Research Objective Of Several Groups Due To The Lack Of Efficient And Safe Drug Treatment. In This Sense,Cannabinoid Receptor 1 (Cbi) Has Attracted Interest Because Of Its Role In Food Intake And Metabolic Balance,Two Targets In The Control Of Metabolic Syndrome. In This Work,Novel 1,5-Diaryl Pyrazole Derivatives Were Synthesized In Accordance With The Pki Prediction Of A Previously Reported Comfa Model By Our Group. To Further Investigate The Biological Activity Of These Compounds In Metabolic Disorders,Their Hypoglycemic Activity In An In Vivo Model Was Tested. Interestingly,A High Degree Of Correlation Was Observed Between The Predicted Pk(I) And Hypoglycemic Effect 7 H After Administration. Compounds 4,9 And 13 Showed The Most Significant Plasma Glucose Reduction With Decreases Of 60%,64% And 60% Respectively. This Result Not Only Surpasses The Activity Of The Lead Rimonabant,But Also That Of The Reference Drug Glibenclamide. Moreover,Pass Prediction And Molecular Docking In An Excellent Validated Homology Model Of Cbi Suggest That These Compounds Would Probably Act As Cbi Antagonists/inverse Agonists And Therefore,Antiobesity Agents. The Ligand Receptor Complexes Demonstrate That 1,5-Diaryl Pyrazole Derivatives Bind To The Proposed Binding Site Where A Hydrophobic Moiety Interacts With The Phenyl Rings In The Pyrazole Nucleus And Lys192 Forms A Hydrogen Bond With The Oxygen Of The Carbonyl Group. Dynamics Simulations Were Also Carried Out To Study The Stability Of The Ligand Receptor Complexes Where The Most Active Compounds Showed Smaller Delta G Values And More Hydrogen Bonds Throughout The Simulation. These Compounds Are Considered Useful Leads For Further Optimization In The Treatment Of Such Metabolic Illnesses. (C) 2013 Elsevier Masson Sas. All Rights Reserved.
Doi:10.1016/j.Ejmech.2013.07.054